Hematologic Malignancy
Small Lymphocytic Lymphoma
CI-CAN-00003981SLLExplore in graph →
Hematologic129 active trials
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003981SLLExplore in graph →
Clinical trials
479 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (108)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05023980 | A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)(BRUIN-CLL-313) | active not recruiting | Phase 3 | 282 | Loxo Oncology, Inc.INDUSTRY | 20 | Sep 25, 2026 | clinicaltrials |
| NCT05963074 | A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia(TAILOR) | active not recruiting | Phase 2 | 333 | Janssen Research & Development, LLC |
| 8 |
| Sep 25, 2026 |
| clinicaltrials |
| NCT02629809 | Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia | active not recruiting | Phase 2 | 81 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06291220 | A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)(453 Ph1 CLL) | active not recruiting | Phase 1 | 4 | AbbVieINDUSTRY | 5 | Sep 11, 2026 | clinicaltrials |
| NCT03625037 | First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma(EPCORE™ NHL-1) | active not recruiting | Phase 1 / Phase 2 | 666 | GenmabINDUSTRY | 15 | Sep 9, 2026 | clinicaltrials |
| NCT04542824 | Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)(EPCORE™ NHL-3) | active not recruiting | Phase 1 / Phase 2 | 78 | GenmabINDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04623541 | Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome(EPCORE™ CLL-1) | active not recruiting | Phase 1 / Phase 2 | 194 | GenmabINDUSTRY | 12 | Sep 9, 2026 | clinicaltrials |
| NCT03824483 | Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) | active not recruiting | Phase 2 | 230 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT02048813 | Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | active not recruiting | Phase 3 | 529 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT03701282 | Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia | active not recruiting | Phase 3 | 720 | National Cancer Institute (NCI)NIH | 2 | Aug 28, 2026 | clinicaltrials |
| NCT03737981 | Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia | active not recruiting | Phase 3 | 465 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT06970743 | A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors(CaDAnCe-303) | active not recruiting | Phase 3 | 153 | BeOne MedicinesINDUSTRY | 2 | Aug 24, 2026 | clinicaltrials |
| NCT02160015 | Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery | active not recruiting | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04007029 | Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia | active not recruiting | Phase 1 | 24 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT02966756 | A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | active not recruiting | Phase 2 | 66 | AbbVieINDUSTRY | 4 | Aug 19, 2026 | clinicaltrials |
| NCT02756897 | Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia | active not recruiting | Phase 2 | 234 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT02846623 | Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome | active not recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT03774654 | CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) | active not recruiting | Phase 1 | 13 | Baylor College of MedicineOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT04419519 | Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax | active not recruiting | Phase 2 | 81 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT03331198 | Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) | active not recruiting | Phase 1 / Phase 2 | 320 | Juno Therapeutics, a Subsidiary of CelgeneINDUSTRY | 2 | Jul 6, 2026 | clinicaltrials |
| NCT02339922 | Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma | active not recruiting | Phase 2 | 33 | University of WashingtonOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT01815749 | Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 30 | City of Hope Medical CenterOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT02007044 | Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia | active not recruiting | Phase 2 | 66 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT03277729 | A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas | active not recruiting | Phase 1 / Phase 2 | 53 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT01787409 | Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency | active not recruiting | N/A | 565 | Mayo ClinicOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT03162536 | A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | active not recruiting | Phase 1 / Phase 2 | 190 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04505254 | Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia | active not recruiting | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT03960840 | Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL | active not recruiting | Phase 1 / Phase 2 | 217 | Novartis PharmaceuticalsINDUSTRY | 8 | Jun 4, 2026 | clinicaltrials |
| NCT04722172 | A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL | active not recruiting | Phase 2 | 55 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT01351896 | Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | active not recruiting | Phase 2 | 49 | National Cancer Institute (NCI)NIH | 1 | May 27, 2026 | clinicaltrials |
| NCT05718869 | Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study | active not recruiting | Phase 2 | 26 | City of Hope Medical CenterOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT02029443 | ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia | active not recruiting | Phase 1 / Phase 2 | 306 | Acerta Pharma BVINDUSTRY | 3 | May 5, 2026 | clinicaltrials |
| NCT01500733 | PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | active not recruiting | Phase 2 | 86 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Apr 28, 2026 | clinicaltrials |
| NCT03479268 | Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 18 | City of Hope Medical CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT04666038 | Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)(BRUIN CLL-321) | active not recruiting | Phase 3 | 238 | Loxo Oncology, Inc.INDUSTRY | 24 | Apr 24, 2026 | clinicaltrials |
| NCT05020678 | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers | active not recruiting | Phase 1 | 150 | Nkarta, Inc.INDUSTRY | 2 | Apr 20, 2026 | clinicaltrials |
| NCT02514083 | A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL | active not recruiting | Phase 2 | 29 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Apr 14, 2026 | clinicaltrials |
| NCT01589302 | PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia | active not recruiting | Phase 2 | 154 | Kami Maddocks, MDOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT02952508 | Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom(CLOVER-WaM) | active not recruiting | Phase 2 | 120 | Cellectar Biosciences, Inc.INDUSTRY | 11 | Mar 18, 2026 | clinicaltrials |
| NCT05624554 | A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008) | active not recruiting | Phase 3 | 300 | Merck Sharp & Dohme LLCINDUSTRY | 21 | Mar 16, 2026 | clinicaltrials |
| NCT03336333 | A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL(SEQUOIA) | active not recruiting | Phase 3 | 590 | BeiGeneINDUSTRY | 15 | Mar 9, 2026 | clinicaltrials |
| NCT05479994 | Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | active not recruiting | Phase 2 | 100 | BeiGeneINDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT04624633 | Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL | active not recruiting | Phase 2 | 29 | Jennifer R. Brown, MD, PhDOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT05677919 | Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia | active not recruiting | Phase 2 | 72 | Mayo ClinicOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT04965493 | A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)(BRUIN CLL-322) | active not recruiting | Phase 3 | 600 | Loxo Oncology, Inc.INDUSTRY | 23 | Jan 29, 2026 | clinicaltrials |
| NCT01199562 | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant | active not recruiting | — | 153 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT04843904 | Safe Accelerated Venetoclax Escalation in CLL(SAVE) | active not recruiting | Phase 1 | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT03961672 | Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | active not recruiting | Phase 2 | 15 | City of Hope Medical CenterOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT02153580 | Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia | active not recruiting | Phase 1 | 37 | City of Hope Medical CenterOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT04072458 | A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies | active not recruiting | Phase 1 | 30 | Bio-Path Holdings, Inc.INDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
Data updated 5 days agoSource updated Sep 25, 2026source: clinicaltrials